SI3480215T1 - Protitelo proti-HER2 in njegov konjugat - Google Patents
Protitelo proti-HER2 in njegov konjugatInfo
- Publication number
- SI3480215T1 SI3480215T1 SI201431847T SI201431847T SI3480215T1 SI 3480215 T1 SI3480215 T1 SI 3480215T1 SI 201431847 T SI201431847 T SI 201431847T SI 201431847 T SI201431847 T SI 201431847T SI 3480215 T1 SI3480215 T1 SI 3480215T1
- Authority
- SI
- Slovenia
- Prior art keywords
- conjugate
- her2 antibody
- her2
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6805—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a vinca alkaloid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310586326 | 2013-11-19 | ||
EP18204950.2A EP3480215B8 (en) | 2013-11-19 | 2014-11-18 | Anti-her2 antibody and conjugate thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SI3480215T1 true SI3480215T1 (sl) | 2021-12-31 |
Family
ID=53178934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201431847T SI3480215T1 (sl) | 2013-11-19 | 2014-11-18 | Protitelo proti-HER2 in njegov konjugat |
Country Status (19)
Country | Link |
---|---|
US (1) | US10087260B2 (sl) |
EP (2) | EP3480215B8 (sl) |
JP (2) | JP6326137B2 (sl) |
KR (3) | KR101854443B1 (sl) |
CN (3) | CN110240655B (sl) |
AU (1) | AU2014352475B2 (sl) |
CA (1) | CA2919359C (sl) |
CY (1) | CY1124651T1 (sl) |
DK (2) | DK3072907T3 (sl) |
ES (1) | ES2879799T3 (sl) |
HR (1) | HRP20211023T1 (sl) |
HU (1) | HUE055269T2 (sl) |
LT (1) | LT3480215T (sl) |
PL (1) | PL3480215T3 (sl) |
PT (1) | PT3480215T (sl) |
RS (1) | RS62157B1 (sl) |
RU (1) | RU2656161C1 (sl) |
SI (1) | SI3480215T1 (sl) |
WO (1) | WO2015074528A1 (sl) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3480215B8 (en) * | 2013-11-19 | 2021-07-28 | RemeGen Co., Ltd. | Anti-her2 antibody and conjugate thereof |
KR101796277B1 (ko) * | 2016-04-12 | 2017-11-13 | 앱클론(주) | 안정성이 개선된 her2에 특이적으로 결합하는 항체 |
AU2019330680A1 (en) * | 2018-08-29 | 2020-04-23 | Remegen Co., Ltd. | Use of anti-HER2 antibody-drug conjugate in treating urothelial carcinoma |
CN111433188B (zh) | 2018-12-17 | 2023-08-01 | 荣昌生物制药(烟台)股份有限公司 | 一种用于抗体药物偶联物的连接子及其应用 |
CN109498816A (zh) * | 2019-01-07 | 2019-03-22 | 合肥瀚科迈博生物技术有限公司 | 一种抗体偶联药物的制备方法 |
US20210238305A1 (en) * | 2019-03-01 | 2021-08-05 | Remegen Co., Ltd. | Antibody for her2 concomitant diagnosis immunohistochemical detection and application thereof |
PT3811979T (pt) | 2019-03-26 | 2024-01-02 | Remegen Co Ltd | Preparação farmacêutica de conjugado fármaco anticorpo anti-her2 |
CN111939267A (zh) * | 2019-05-17 | 2020-11-17 | 百奥泰生物制药股份有限公司 | 抗体-药物偶联物制剂、制备方法及应用 |
WO2021097220A1 (en) | 2019-11-15 | 2021-05-20 | Seagen Inc. | Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate |
EP4093774A4 (en) * | 2020-01-23 | 2024-01-17 | Bioatla Inc | CONDITIONALLY ACTIVE ANTI-HER2 ANTIBODIES, ANTIBODY FRAGMENTS, THEIR IMMUNOCONJUGATES AND RELATED USES |
CN112353947A (zh) * | 2020-11-23 | 2021-02-12 | 荣昌生物制药(烟台)股份有限公司 | 一种含二甲双胍和抗体药物偶联物的药物组合物及其应用 |
CN112402616A (zh) * | 2020-11-23 | 2021-02-26 | 荣昌生物制药(烟台)股份有限公司 | 一种含环丙沙星和抗体药物偶联物的药物组合物及其应用 |
CN114796519A (zh) * | 2021-01-27 | 2022-07-29 | 南开大学 | 一种蛋白质偶联小分子药物的制备和应用 |
WO2022174775A1 (en) * | 2021-02-18 | 2022-08-25 | Remegen Co., Ltd. | Use of antibody-drug conjugate targeting her2 in treatment of specific breast cancer |
US11814394B2 (en) * | 2021-11-16 | 2023-11-14 | Genequantum Healthcare (Suzhou) Co., Ltd. | Exatecan derivatives, linker-payloads, and conjugates and thereof |
CN114736300B (zh) * | 2022-06-09 | 2022-08-19 | 苏州百道医疗科技有限公司 | 一种抗her2重组兔单克隆抗体及其应用 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1189641B1 (en) | 1999-06-25 | 2009-07-29 | Genentech, Inc. | HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
PT2283867E (pt) | 1999-06-25 | 2014-08-29 | Immunogen Inc | Métodos de tratamento usando conjugados de anticorpo antierbb- maitansinóide |
US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
CN1993146A (zh) | 2004-06-01 | 2007-07-04 | 健泰科生物技术公司 | 抗体-药物偶联物和方法 |
CN114053429A (zh) * | 2004-06-01 | 2022-02-18 | 健泰科生物技术公司 | 抗体-药物偶联物和方法 |
KR20160096228A (ko) | 2004-07-22 | 2016-08-12 | 제넨테크, 인크. | Her2 항체 조성물 |
PE20090245A1 (es) | 2007-05-08 | 2009-03-17 | Genentech Inc | Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos |
CN101143902B (zh) * | 2007-05-18 | 2010-06-02 | 中国医学科学院医药生物技术研究所 | 抗HER2单链抗体-力达霉素强化融合蛋白HER2(Fv-LDM) |
US20090258005A1 (en) | 2007-05-29 | 2009-10-15 | Trubion Pharmaceuticals Inc. | Therapeutic compositions and methods |
JP2011517555A (ja) * | 2008-03-14 | 2011-06-16 | ジェネンテック, インコーポレイテッド | 薬剤耐性に関連する遺伝的変異 |
TWI574698B (zh) * | 2008-03-18 | 2017-03-21 | 建南德克公司 | 抗her2抗體-藥物結合物及化療劑之組合及使用方法 |
EP2327177B1 (en) * | 2008-09-19 | 2017-11-08 | Telefonaktiebolaget LM Ericsson (publ) | Protection mechanism for a communications network |
CN102030827B (zh) * | 2009-09-25 | 2014-09-24 | 上海抗体药物国家工程研究中心有限公司 | 一种高亲和力的抗her2单克隆抗体 |
WO2011084496A1 (en) * | 2009-12-16 | 2011-07-14 | Abbott Biotherapeutics Corp. | Anti-her2 antibodies and their uses |
CN102167742B (zh) * | 2010-02-25 | 2014-05-14 | 上海百迈博制药有限公司 | 一种全人源抗her2单克隆抗体、其制备方法及用途 |
TW201141519A (en) * | 2010-03-04 | 2011-12-01 | Symphogen As | Anti-HER2 antibodies and compositions |
US8609095B2 (en) * | 2010-03-04 | 2013-12-17 | Symphogen A/S | Anti-HER2 antibodies and compositions |
JP6082344B2 (ja) | 2010-05-27 | 2017-02-15 | ゲンマブ エー/エス | Her2エピトープに対するモノクローナル抗体 |
CA3051311A1 (en) * | 2010-05-27 | 2011-12-01 | Genmab A/S | Monoclonal antibodies against her2 |
US9193791B2 (en) * | 2010-08-03 | 2015-11-24 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects |
KR101933990B1 (ko) | 2012-05-02 | 2018-12-31 | 심포젠 에이/에스 | 인간화 panher 항체 조성물 |
EP3480215B8 (en) * | 2013-11-19 | 2021-07-28 | RemeGen Co., Ltd. | Anti-her2 antibody and conjugate thereof |
-
2014
- 2014-11-18 EP EP18204950.2A patent/EP3480215B8/en active Active
- 2014-11-18 JP JP2016537121A patent/JP6326137B2/ja active Active
- 2014-11-18 LT LTEP18204950.2T patent/LT3480215T/lt unknown
- 2014-11-18 KR KR1020167012018A patent/KR101854443B1/ko active IP Right Grant
- 2014-11-18 ES ES18204950T patent/ES2879799T3/es active Active
- 2014-11-18 CN CN201811053363.6A patent/CN110240655B/zh active Active
- 2014-11-18 DK DK14864053.5T patent/DK3072907T3/en active
- 2014-11-18 KR KR1020187012035A patent/KR101936697B1/ko active IP Right Grant
- 2014-11-18 PT PT182049502T patent/PT3480215T/pt unknown
- 2014-11-18 CN CN201480006648.8A patent/CN105008398B/zh active Active
- 2014-11-18 RU RU2016106339A patent/RU2656161C1/ru active
- 2014-11-18 US US15/037,104 patent/US10087260B2/en active Active
- 2014-11-18 CN CN201810804801.1A patent/CN109320612B/zh active Active
- 2014-11-18 AU AU2014352475A patent/AU2014352475B2/en active Active
- 2014-11-18 WO PCT/CN2014/091332 patent/WO2015074528A1/zh active Application Filing
- 2014-11-18 SI SI201431847T patent/SI3480215T1/sl unknown
- 2014-11-18 CA CA2919359A patent/CA2919359C/en active Active
- 2014-11-18 HU HUE18204950A patent/HUE055269T2/hu unknown
- 2014-11-18 KR KR1020187036881A patent/KR101993136B1/ko active IP Right Grant
- 2014-11-18 DK DK18204950.2T patent/DK3480215T5/da active
- 2014-11-18 PL PL18204950T patent/PL3480215T3/pl unknown
- 2014-11-18 EP EP14864053.5A patent/EP3072907B1/en active Active
- 2014-11-18 RS RS20210939A patent/RS62157B1/sr unknown
-
2018
- 2018-04-13 JP JP2018077954A patent/JP6728264B2/ja active Active
-
2021
- 2021-06-28 HR HRP20211023TT patent/HRP20211023T1/hr unknown
- 2021-08-06 CY CY20211100704T patent/CY1124651T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL261743B (en) | and their uses 33–il antibodies against | |
HK1232243A1 (zh) | 抗- 抗體及其用途 | |
HK1217956A1 (zh) | 新的抗體綴合物及其用途 | |
IL261547B (en) | Antibodies against pesidine and their uses | |
IL245040B (en) | Antibodies against pdgfr-beta and their uses | |
SI3480215T1 (sl) | Protitelo proti-HER2 in njegov konjugat | |
IL243974B (en) | Antibodies against –prlr and uses | |
ZA201508896B (en) | Anti-c10orf54 antibodies and uses thereof | |
IL240517A0 (en) | Antibodies against b7–h4 and immunoconjugates | |
SG11201509116VA (en) | Anti-tweakr antibodies and uses thereof | |
IL240440A0 (en) | Antibodies against her2 with a high level of galactosylation and their uses | |
HK1223950A1 (zh) | 單克隆 抗體及其用途 |